Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Head and Neck Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Laryngeal Diseases 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × monalizumab × Head & Neck × Clear all
NCT04590963 2026-06-01

INTERLINK-1

AstraZeneca

Phase 3 Active not recruiting
370 enrolled 21 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT02643550 2023-05-12

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Innate Pharma

Phase 1/2 Completed
143 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡